Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNASDAQ:CMPXNASDAQ:LGSTNASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.43+0.2%$5.46$3.79▼$14.60$272.06M-0.921.47 million shs690,836 shsCMPXCompass Therapeutics$2.09-0.5%$1.91$0.77▼$4.08$289.01M1.4920,626 shs529,883 shsLGSTSemper Paratus Acquisition$4.51$4.52$4.08▼$12.03$71.35M-0.0830,930 shs12,596 shsPROKProKidney$0.71-3.6%$0.80$0.46▼$4.35$207.99M1.5675,367 shs637,917 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics+0.18%+1.50%+13.48%-53.31%-48.68%CMPXCompass Therapeutics-0.48%-0.48%+0.97%-28.42%+33.97%LGSTSemper Paratus Acquisition0.00%0.00%0.00%0.00%0.00%PROKProKidney-3.57%-11.90%-21.92%-52.63%-80.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics1.9407 of 5 stars3.51.00.00.02.61.70.6CMPXCompass Therapeutics3.8792 of 5 stars4.63.00.00.03.05.00.0LGSTSemper Paratus AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APROKProKidney1.6002 of 5 stars3.30.00.00.00.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$21.00286.74% UpsideCMPXCompass Therapeutics 3.11Buy$13.13527.99% UpsideLGSTSemper Paratus Acquisition 0.00N/AN/AN/APROKProKidney 2.50Moderate Buy$5.00603.63% UpsideCurrent Analyst Ratings BreakdownLatest LGST, CMPX, CADL, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.004/2/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025CMPXCompass TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.004/1/2025CMPXCompass TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/1/2025CMPXCompass TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,267.16N/AN/A$0.44 per share12.34CMPXCompass Therapeutics$850K340.01N/AN/A$1.17 per share1.79LGSTSemper Paratus AcquisitionN/AN/A$0.33 per share13.74($1.10) per shareN/APROKProKidney$306K679.71N/AN/A($4.84) per share-0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)CMPXCompass Therapeutics-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)LGSTSemper Paratus Acquisition$4.41MN/A0.00∞N/AN/A-21.83%3.10%N/APROKProKidney-$35.47M-$0.60N/AN/AN/AN/AN/A-10.24%8/8/2025 (Estimated)Latest LGST, CMPX, CADL, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 million3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/A2/27/2025Q4 2024CMPXCompass Therapeutics-$0.10-$0.11-$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ALGSTSemper Paratus AcquisitionN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel TherapeuticsN/A1.181.18CMPXCompass TherapeuticsN/A31.8431.84LGSTSemper Paratus AcquisitionN/A0.220.22PROKProKidneyN/A17.0817.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%CMPXCompass Therapeutics68.43%LGSTSemper Paratus AcquisitionN/APROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%CMPXCompass Therapeutics29.80%LGSTSemper Paratus Acquisition56.60%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableCMPXCompass Therapeutics20138.28 million98.38 millionNot OptionableLGSTSemper Paratus Acquisition2,02115.82 million6.86 millionNot OptionablePROKProKidney3292.70 million170.65 millionOptionableLGST, CMPX, CADL, and PROK HeadlinesRecent News About These CompaniesProKidney quarterly loss grows as it nears two key milestonesMay 15, 2025 | journalnow.comProKidney Reports First Quarter 2025 Financial Results and Business HighlightsMay 12, 2025 | globenewswire.comAnother Big Office Landlord Tests Sales ClimateMay 12, 2025 | bankerandtradesman.comPROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comProKidney (PROK) Expected to Announce Quarterly Earnings on FridayMay 4, 2025 | marketbeat.comWhy ProKidney Corp.’s (PROK) Stock Is Down 6.09%April 28, 2025 | aaii.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Purchases 387,393 Shares of StockApril 25, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 7.90%April 17, 2025 | aaii.comProKidney Corp. (NASDAQ:PROK) Insider Buys $195,716.65 in StockApril 17, 2025 | insidertrades.comGreensboro’s Once Great Win Is Now A ProKidney FailureApril 16, 2025 | rhinotimes.comControl Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 15, 2025 | insidertrades.comWhy ProKidney Corp.’s (PROK) Stock Is Down 9.90%April 10, 2025 | aaii.comWhy ProKidney Corp.’s (PROK) Stock Is Down 14.87%April 8, 2025 | aaii.comProKidney Corp.March 30, 2025 | wsj.comHere's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn SituationMarch 27, 2025 | finance.yahoo.comDown -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)March 21, 2025 | zacks.comProKidney reports larger loss in 2024 as production resumesMarch 18, 2025 | journalnow.comProKidney reports FY24 EPS (62c), consensus (59c)March 17, 2025 | markets.businessinsider.comProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney DiseaseMarch 17, 2025 | quiverquant.comProKidney Reports Full Year 2024 Financial Results and Business HighlightsMarch 17, 2025 | globenewswire.comWhy ProKidney Corp.’s (PROK) Stock Is Down 10.96%February 26, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGST, CMPX, CADL, and PROK Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.43 +0.01 (+0.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.53 +0.10 (+1.92%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Compass Therapeutics NASDAQ:CMPX$2.09 -0.01 (-0.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.18 +0.10 (+4.55%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Semper Paratus Acquisition NASDAQ:LGSTSemper Paratus Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire companies operating in the transportation, supply chain, and logistics industries. Semper Paratus Acquisition Corporation was incorporated in 2021 and is based in New York, New York. Semper Paratus Acquisition Corporation operates as a subsidiary of Ssvk Associates, Llc.ProKidney NASDAQ:PROK$0.71 -0.03 (-3.57%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.72 +0.01 (+1.18%) As of 05/23/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
